Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen; LYO-X GmbH, Allschwil, Switzerland; Department of Internal Medicine, Charité-Universitätsmedizin, Berlin, Germany; Department for Hemato-Oncology, Comprehensive Cancer Center, Charité-University Medicine, Berlin, Germany; Medizinischen Klinik m.S. Hepatologie und Gastroenterologie, Berlin, Georgia; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; Hannover Medical School, Hannover, Germany; Onkologie Praxis, Leer, Germany; Klinikum Ludwigsburg, Ludwigsburg, Germany; Department of Medicine II, University Hospital Freiburg, Freiburg, Germany; Onkologie Praxis, Worms, Germany; Instutut für Radiologie, Berlin, Germany; University of Surrey, Surrey, United Kingdom; CellAct, Dortmund, Germany; CellAct Pharma GmbH, Dortmund, Germany. … Read the rest
Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).… Read the rest
LYO-X is sponsoring the LATSIS Symposium on Personalised Medicine to be held at the ETH Zurich June 27–29 2016. Personalised medicine has a number of quite attractive advantages. Treatments tailored to the individual patient, for example by therapy selection based on diagnostic tools or by individualised dosing, should improve the effect, lower side effects and lower costs by avoiding ineffective treatments. It appears to be an obvious solution given the situation we have today in the health care system. However, despite the advantages most drugs are still developed as a one-fits-all solution without any diagnostic tools.… Read the rest
We were very kindly invited to the 20. Pharmacokinetics/Pharmacodynamics Expert Meeting in Berlin April 14th – 16th 2016. It will be a great opportunity to meet the German PKPD experts. There is an attractive agenda including:
- Systems Pharmacology
Methods, Applications, Opportunities and Challenges
- Dose Finding in Phase II for Confirmatory Clinical Trials
Overview, Methods, Good Practices and Examples
- PK/PD of Locally Applied Drugs
Considerations for (Sub-)Cutaneous and Ocular Administration of Pharmaceuticals
Of course we are in the Systems Pharmacology session where we will talk about the “Introduction to Concepts and Methods of Systems Pharmacology”.… Read the rest
We will be at ACoP6 with our partner Lixoft meeting the pharmacometrics community and teaching at the Monolix Suite workshop.
I’m looking very much forward to the event. It will be great to meet all my friends and colleagues especially everyone living in the US who I have not seen for quite a while.
I’m going to talk about Simulx on day two of the Monolix Suite workshop which I’m especially proud of. It is such an elegant and powerful solution for NLME simulations.… Read the rest
LYO-X will be at the Life Science Forum Basel this coming Thursday, June 18th. We will address the very relevant question “Why Investing Millions in Generating Data?” and show “How to Use Systems Pharmacology to Make the Most of Your Data”. Join us at this event with a very exciting program. The event is at the Pharmazentrum/Biozentrum of the University of Base and starts midday. For more details see the PROGRAM.… Read the rest
LYO-X is helping to determine the optimal dose of ZMapp™, a monoclonal antibody cocktail, for the treatment of Ebola virus disease. This project shows another reason why it is critical to determine the right dose. With no approved vaccine or medicine the sudden outbreak of Ebola virus disease in February 2014 caught the world off guard. Optimal dosing in such circumstances is not only a matter of safety and efficacy but also of providing treatment to every patient in need. Modelling approaches can help in such situations to integrate sparse data to inform the right dose or to put forward hypotheses that can be tested in a targeted way to derive better information on the right dose and regimen.… Read the rest
LYO-X will be at the QSP congress in Boston Jan 28th for Lixoft. We will present the Monolix suite and demonstrate how it is a success factor for your Systems Pharmacology projects. We will also host a roundtable to collect inputs from our partners on what the next critical components are that need to be implemented in the Monolix suite.
Join us in Boson. The attendance is excellent with all the Systems Pharmacology leaders who are participating. I expect a great meeting with lots of engaging discussion.… Read the rest
LYO-X presented at the Lift Basel 2014 (https://lnkd.in/dX7bTmM) innovation conference. It was interesting to hear all the futuristic and exciting talks and to discuss with the presenters. The conference has definitely helped me to get inspired and to continue to push the innovation boundary for computational methods in drug development. LYO-X is committed to bring this innovation in Systems Pharmacology also to small Biotechnology companies who do not have the competitive advantage of a own Pharmacometrics team. See http://videos.liftconference.com for more videos on youtube with exciting talks from the LIFT conference.… Read the rest